Relative incidence of acute adverse events with ferumoxytol compared to other intravenous iron compounds: A matched cohort study

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Wetmore, James B ^a,b   Weinhandl, Eric D ^a   Zhou, Jincheng ^a,c   Gilbertson, David T ^a  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC GLUCONATE; FERUMOXYTOL; IRON DEXTRAN; IRON SACCHARATE; IRON DERIVATIVE; MAGNETITE;

AGED; ANAPHYLAXIS; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMERGENCY WARD; FEMALE; HOSPITALIZATION; HUMAN; HYPOTENSION; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MEDICARE; NON DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; COMPARATIVE STUDY; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; STATISTICAL ANALYSIS;

ADMINISTRATION, INTRAVENOUS; COHORT STUDIES; FERROSOFERRIC OXIDE; HUMANS; INCIDENCE; IRON COMPOUNDS; MATCHED-PAIR ANALYSIS; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 85011277376     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0171098     Document Type: Article

References (45)

1. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016; 387: 907-916. doi: 10.1016/S0140-6736(15)60865-0 PMID: 26314490
2. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador G, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis. 2001; 38: 803-812. doi: 10.1053/ajkd.2001. 27699 PMID: 11576884
3. Hsu CY. Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens. 2002; 11: 337-341. PMID: 11981265
4. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002; 162: 1401-1408. PMID: 12076240
5. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol. 2009; 4: 57-61. doi: 10.2215/CJN.01670408 PMID: 18987297
6. National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47(Suppl 3): S1-S146.
7. KDIGO Anemia Work Group. KDIGO Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 2: 288-335.
8. Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014; 123: 615-624. doi: 10.1182/blood-2013-06-508325 PMID: 24297872
9. Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the United States. JAMA. 1997; 277: 973-976. PMID: 9091669
10. Cogswell ME, Looker AC, Pfeiffer CM, Cook JD, Lacher DA, Beard JL, et al. Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003-2006. Am J Clin Nutr. 2009; 89: 1334-1342. doi: 10.3945/ajcn. 2008.27151 PMID: 19357218
11. McLean E, Cogswell M, Egli I, Wojdyla D, de BB. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr. 2009; 12: 444-454. doi: 10.1017/S1368980008002401 PMID: 18498676
12. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995; 25: 433-439. PMID: 7872321
13. Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011; 11: 4. doi: 10.1186/1471-2326-11-4 PMID: 21942989
14. Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, Haya-Palazuelos J, Ciria-Recasens M, Manasanch J, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013; 29: 291-303. doi: 10.1185/03007995.2012.761599 PMID: 23252877
15. Kruske SG, Ruben AR, Brewster DR. An iron treatment trial in an aboriginal community: improving nonadherence. J Paediatr Child Health. 1999; 35: 153-158. PMID: 10365352
16. Fishbane S, Ungureanu V, Maesaka JK, Kaupke CJ, Lim V, Wish J. Safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996; 28: 529-534. PMID: 8840942
17. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999; 33: 464-470. PMID: 10070910
18. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis. 2001; 37: 743-749. PMID: 11273874
19. Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextrantolerant patients. Kidney Int. 2003; 63: 217-224. doi: 10.1046/j.1523-1755.2003.00703.x PMID: 12472786
20. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21: 378-382. doi: 10.1093/ndt/gfi253 PMID: 16286429
21. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant. 2004; 19: 1571-1575. doi: 10.1093/ndt/gfh185 PMID: 15150356
22. Sav T, Tokgoz B, Sipahioglu MH, Deveci M, Sari I, Oymak O, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail. 2007; 29: 423-426. doi: 10.1080/08860220701278208 PMID: 17497463
23. Auerbach M, Al TK. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int. 2008; 73: 528-530. doi: 10.1038/sj.ki.5002779 PMID: 18274543
24. Okam MM, Mandell E, Hevelone N, Wentz R, Ross A, Abel GA. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol. 2012; 87: E123-E124. doi: 10.1002/ajh. 23322 PMID: 22965928
25. Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014; 9: 705-712. doi: 10.2215/CJN.05320513 PMID: 24458078
26. Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014; 29: 833-842. doi: 10.1093/ndt/gft251 PMID: 23963731
27. Bircher AJ, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am. 2014; 34: 707-723. doi: 10.1016/j.iac.2014.04.013 PMID: 25017687
28. Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfus Altern Transfus Med. 2007; 9: 8-36.
29. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program. 2010; 2010: 338-347. doi: 10.1182/asheducation-2010.1.338 PMID: 21239816
30. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran-a comparison of two products. Am J Nephrol. 2000; 20: 455-462. PMID: 11146312
31. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008; 19: 1599-1605. doi: 10.1681/ASN. 2007101156 PMID: 18525001
32. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4: 386-393. doi: 10.2215/CJN.02840608 PMID: 19176796
33. Food & Drug Administration. FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). Available: http://www.fda.gov/Drugs/DrugSafety/ucm440138.htm. Accessed: August 16, 2016
34. Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levnenson M, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015; 314: 2062-2068. doi: 10.1001/jama.2015.15572 PMID: 26575062
35. Airy M, Mandayam S, Mitani AA, Chang TI, Ding VY, Brookhart MA, et al. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. Nephrol Dial Transplant. 2015; 30: 2068-2075. doi: 10.1093/ndt/gfv305 PMID: 26311216
36. Weinhandl ED, Arneson TJ, St Peter WL. Clinical outcomes associated with receipt of integrated pharmacy services by hemodialysis patients: a quality improvement report. Am J Kidney Dis. 2013; 62: 557-567. doi: 10.1053/j.ajkd.2013.02.360 PMID: 23597860
37. Rubin R. New anthrax treatment approved. JAMA. 2015; 313: 1704.
38. Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm. 2012; 69: 310-320. doi: 10.2146/ajhp110262 PMID: 22302256
39. Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010; 85: 650-654. doi: 10.1002/ajh. 21794 PMID: 20661919
40. Auerbach M, Kane RC. Caution in making inferences from FDA's Adverse Event Reporting System. Am J Health Syst Pharm. 2012; 69: 922-923. doi: 10.2146/ajhp120138 PMID: 22610021
41. Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol. 2014; 89: 646-650. doi: 10.1002/ajh.23712 PMID: 24639149
42. Auerbach M, Strauss W, Auerbach S, Rineer S, Bahrain H. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Am J Hematol. 2013; 88: 944-947. doi: 10.1002/ajh.23534 PMID: 23828252
43. Schiller B, Bhat P, Sharma A. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther. 2014; 36: 70-83. doi: 10.1016/j. clinthera.2013.09.028 PMID: 24315802
44. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antinflammatory drugs. Adv Inflamm Res. 1984; 6: 1-7.
45. Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixtytwo drugs approved from 2006 to 2010. Drug Saf. 2014; 37: 283-294. doi: 10.1007/s40264-014-0150-2 PMID: 24643967